Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Radboud University Medical Center
Columbia University
University of Ulm
Beijing GoBroad Hospital
University of Alabama at Birmingham
Institut Cancerologie de l'Ouest
The First Affiliated Hospital with Nanjing Medical University
University of Pennsylvania
Virginia Commonwealth University
Institute of Hematology & Blood Diseases Hospital, China
Hospices Civils de Lyon
University Hospital, Toulouse
North Eastern German Society of Gynaecological Oncology
AIO-Studien-gGmbH
Gruppo Italiano Malattie EMatologiche dell'Adulto
Therapeutic Advances in Childhood Leukemia Consortium
Mario Negri Institute for Pharmacological Research
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Augusta University
Dana-Farber Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium
University Health Network, Toronto
University of Vermont
Roswell Park Cancer Institute
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
Cantonal Hospital of St. Gallen
City of Hope Medical Center
University of Pennsylvania
Zhejiang University
Big Ten Cancer Research Consortium
Hangzhou Cheetah Cell Therapeutics Co., Ltd
Gruppo Italiano Malattie EMatologiche dell'Adulto
University Hospital Southampton NHS Foundation Trust
Hackensack Meridian Health
Washington University School of Medicine
Institut Cancerologie de l'Ouest
Swiss Cancer Institute
Swiss Cancer Institute
Samsung Medical Center
British Columbia Cancer Agency
Sydney Children's Hospitals Network
Fox Chase Cancer Center
British Columbia Cancer Agency
Therapeutic Advances in Childhood Leukemia Consortium
University of Ulm